United Therapeutics Corporation UTHR shares plunged around 9% on Monday after the company announced that regulatory issues will delay the planned U.S. launch of RemoSynch - an implantable pump for ...
It took Novartis' Sandoz years to reach the market with a generic to United Therapeutics’ pulmonary arterial hypertension drug Remodulin, but last month, the company managed to do just that. Now, ...
DUBLIN--(BUSINESS WIRE)--The "Remodulin - Drug Insight, 2019" report has been added to ResearchAndMarkets.com's offering. Remodulin Drug Insight, 2019 highlights the drug marketed details and the ...
Additional EU nations will similarly clear IV delivery route for prostacylclin vasodilator. The French regulator, Agence Francaise de Securite Sanitaire des Produits de Sante (AFSSAPS), has cleared ...
Liquidia and Sandoz are poised to introduce a generic, subcutaneous version of United Therapeutics’ Remodulin to the U.S. market. Details of the planned launch emerged after Liquidia’s partner secured ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results